Collegium Q2 revenue rises 6%

Collegium Pharmaceutical

06/08/2026 12:52

Overview
US biopharmaceutical firm's Q2 revenue rose 6% yr/yr, slightly missing analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company completed AZSTARYS acquisition, expanding ADHD portfolio and revenue outlook

Outlook
Collegium lowers 2026 product revenues, net guidance to $825 mln-$855 mln from $865 mln-$895 mln
Company raises 2026 AZSTARYS revenue guidance to $65 mln-$75 mln from $60 mln-$70 mln
Company maintains 2026 JORNAY PM revenue guidance at $190 mln-$200 mln

Result Drivers
ADHD PORTFOLIO GROWTH - Co said strong demand for JORNAY PM and increased prescriber adoption drove ADHD portfolio revenue higher
AZSTARYS ACQUISITION - Co said completion and integration of AZSTARYS added a differentiated ADHD medicine and contributed partial-quarter sales
PAIN PORTFOLIO PRESSURE - Co said pain portfolio provided a solid base but Nucynta franchise revenues declined due to lower net pricing for AG versions

Company press release: ID:nGNX8vvpbs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Miss*
$199.90 mln
$201.21 mln (5 Analysts)
Q2 Adjusted EPS
Beat
$1.92
$1.72 (5 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Collegium Pharmaceutical Inc is $56.00, about 56.7% above its August 5 closing price of $35.74
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
Aug 4 - Harmony Biosciences Q2 WAKIX revenue beats on patient growth
Aug 4 - Pacira Q2 revenue slightly beats estimates; cuts FY outlook
Aug 5 - Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)